Effect Of Bevacizumab On Growth Of Human Nasal Polyposis In Vitro; An Off-Label Use Of Anti-Angiogenic Agent For Nasal Polyposis Treatment

References

• Settipane GA, editor. Epidemiology of nasal polyps In: Allergy and Asthma Proceedings. Oceanside Publications; 1996;17(5):231.
   Google Scholar
• Pearlman AN, Chandra RK, Conley DB, Kern RC. Epidemiology of nasal polyps In: Nasal Polyposis. Berlin, Heidelberg: Springer; 2010:9–15.
   Google Scholar
• Assanasen P, Naclerio RM. Medical and surgical management of nasal polyps. Curr Opin Otolaryngol Head Neck Surg. 2001;9(1):27–36. doi:10.1097/00020840-200102000-00007
   Google Scholar
• Kirtsreesakul V. Update on nasal polyps: etiopathogenesis. J Med Assoc Thailand. 2005;88(12):1966.
   PubMedGoogle Scholar
• Nemati S, Mojtahedi A, Naghavi SE, Banan R, Zia F. Investigating Helicobacter pylori in nasal polyposis using polymerase chain reaction, urease test and culture. Eur Arch Otorhinolaryngol. 2012;269(5):1457–1461. doi:10.1007/s00405-011-1848-822116383
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Yamane H, Shigeta T, Takashima T, Nakai Y. Interaction between fibronectin and eosinophils in the growth of nasal polyps. Laryngoscope. 1999;109(4):557–561. doi:10.1097/00005537-199904000-0000710201740
   PubMed Web of Science ®Google Scholar
• Cao Q, Zhang J. The expression and significance of STAT6, VEGF and MVD in Nasal Polyps. Cancer Res J. 2018;6(2):47. doi:10.11648/j.crj.20180602.12
   Google Scholar
• Haruna S, Nakanishi M, Otori N, Moriyama H. Histopathological features of nasal polyps with asthma association: an immunohistochemical study. Am J Rhinol. 2004;18(3):165–172.15283491
   PubMedGoogle Scholar
• Milanini J, Viñals F, Pouysségur J, Pagès G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem. 1998;273(29):18165–18172. doi:10.1074/jbc.273.29.181659660776
   PubMed Web of Science ®Google Scholar
• Muluk NB, Atasoy P, Arikan OK, Koc C. Role of vascular endothelial growth factor in the pathogenesis of nasal polyps. J Otolaryngol. 2007;36(6):357–366.18076846
   PubMedGoogle Scholar
• Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–1440. doi:10.1016/j.jaci.2015.10.01026654192
   PubMed Web of Science ®Google Scholar
• Hu K-H, Lee F-P, Cheng Y-J, Huang H-M. Vascular endothelial growth factor and children featuring nasal polyps. Int J Pediatr Otorhinolaryngol. 2007;71(1):23–28. doi:10.1016/j.ijporl.2006.08.01816987554
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91(6):804–807. doi:10.1136/bjo.2006.10791217179168
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328–335. doi:10.1016/j.bbrc.2005.05.13215961063
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2004;23(4):792–799. doi:10.1200/JCO.2005.05.098
   Web of Science ®Google Scholar
• Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26(3):352–354. doi:10.1097/00006982-200603000-0001616508438
   PubMed Web of Science ®Google Scholar
• Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275–278. doi:10.1097/00006982-200603000-0000416508426
   PubMed Web of Science ®Google Scholar
• Sasich LD, Sukkari SR. The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). Saudi Pharm J. 2012;20(4):381–385. doi:10.1016/j.jsps.2011.12.00123960813
   PubMed Web of Science ®Google Scholar
• Bachert C, Pawankar R, Zhang L, et al. ICON: chronic rhinosinusitis. World Allergy Organ J. 2014;7(1):1–28. doi:10.1186/1939-4551-7-124383710
   PubMedGoogle Scholar
• Park SK, Lee WJ, Yang YI. Organ culture at the air-liquid interface maintains structural and functional integrities of inflammatory and fibrovascular cells of nasal polyps. Am J Rhinol. 2007;21(4):402–407.17882906
   PubMedGoogle Scholar
• Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335–345. doi:10.1007/s10456-004-8272-215886877
   PubMedGoogle Scholar
• Mygind N, Dahl R, Bachert C. Nasal polyposis, eosinophil dominated inflammation, and allergy. Thorax. 2000;55(suppl 2):S79–S83. doi:10.1136/thorax.55.suppl_2.s7910992568
   PubMed Web of Science ®Google Scholar
• Wittekindt C, Hess A, Bloch W, Sultanie S, Michel O. Immunohistochemical expression of VEGF and VEGF receptors in nasal polyps as compared to normal turbinate mucosa. Eur Arch Otorhinolaryngol. 2002;259(6):294–298. doi:10.1007/s00405-002-0467-912115075
   PubMed Web of Science ®Google Scholar
• Gosepath J, Brieger J, Lehr HA, Mann WJ. Expression, localization, and significance of vascular permeability/vascular endothelial growth factor in Nasal Polyps. Am J Rhinol. 2005;19(1):7–13.15794068
   PubMedGoogle Scholar
• Lee HS, Myers A, Kim J. Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis. Am J Respir Crit Care Med. 2009;180(11):1056–1067. doi:10.1164/rccm.200905-0740OC19762561
   PubMed Web of Science ®Google Scholar
• Zhao M, Yu Z, Li Z, Tang J, Lai X, Liu L. Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: a potential self-regulating mechanism. Oncol Rep. 2017;37(1):601–607. doi:10.3892/or.2016.523127840995
   PubMed Web of Science ®Google Scholar
• Zhang M, Chu S, Zeng F, Xu H. Bevacizumab modulates the process of fibrosis in vitro. Clin Exp Ophthalmol. 2015;43(2):173–179. doi:10.1111/ceo.1237424995375
   PubMed Web of Science ®Google Scholar
• Terasaki H, Sakamoto T, Shirasawa M, et al. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro. Retina. 2015;35(5):1007–1015. doi:10.1097/IAE.000000000000042825627091
   PubMed Web of Science ®Google Scholar
• Walraven M, Homs MYV, van der Veldt AAM, et al. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. Angiogenesis. 2018;21(2):325–334. doi:10.1007/s10456-018-9598-529532289
   PubMed Web of Science ®Google Scholar
• Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck. 2015;37(6):783–787. doi:10.1002/hed.v37.624595923
   PubMed Web of Science ®Google Scholar
• Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2012;33(3):349–351. doi:10.1016/j.amjoto.2011.07.01221917353
   PubMed Web of Science ®Google Scholar
• Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope. 2012;122(3):495–497. doi:10.1002/lary.2250122147664
   PubMed Web of Science ®Google Scholar
• Chen S, Karnezis T, Davidson TM. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121(3):644–646. doi:10.1002/lary.2134521344447
   PubMed Web of Science ®Google Scholar
• Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121(3):636–638. doi:10.1002/lary.2141521344445
   PubMed Web of Science ®Google Scholar
• Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol. 2012;269(2):531–536. doi:10.1007/s00405-011-1721-921805356
   PubMed Web of Science ®Google Scholar
• Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry C. Bevacizumab nasal spray: noninvasive treatment of epistaxis in patients with Rendu-Osler disease. Laryngoscope. 2012;122(5):953–955. doi:10.1002/lary.2323022447341
   PubMed Web of Science ®Google Scholar
• Samson G, Garcia de la Calera A, Dupuis-Girod S, et al. Ex vivo study of bevacizumab transport through porcine nasal mucosa. Eur J Pharm Biopharm. 2012;80(2):465–469. doi:10.1016/j.ejpb.2011.11.00422120685
   PubMed Web of Science ®Google Scholar
• Dupuis-Girod S, Ambrun A, Decullier E, et al. Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trialbevacizumab nasal spray for epistaxis in patients with hhtbevacizumab nasal spray for epistaxis in patients with HHT. JAMA. 2016;316(9):934–942. doi:10.1001/jama.2016.1138727599328
   PubMed Web of Science ®Google Scholar